The effects of SGLT2 inhibitors on increasing Mg levels have also been observed in a patient receiving cisplatin as a chemotherapeutic agent who developed tubulopathy, as well as in other cases of hypomagnesemia due to the administration of other drugs, such as anticalcineurin agents [142]. Here, SLC5A2 is linked to familial primary hypomagnesemia.